Biologics by McKesson Starting the New Year With Momentum

Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was recently selected by Calliditas Therapeutics as the exclusive specialty pharmacy provider for TARPEYOTM (budesonide) delayed release capsules to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression.

TARPEYO, approved by the U.S. Food and Drug Administration (FDA) on December 15, 2021, is the first and only FDA-approved treatment that was specifically designed for this condition. IgAN is a rare, progressive autoimmune disease, which has a high unmet need with more than 50% of patients potentially progressing to end-stage renal disease.

This indication is approved under accelerated approval based on a reduction in proteinuria. It has not been established whether TARPEYO slows kidney function decline in patients with IgAN.

With its innovative PharmacyElite™ program, Biologics will help patients start on TARPEYO quickly by managing access, reimbursement and clinical services with a high degree of efficiency. This integrated approach marries Biologics’ industry-leading, high-touch specialty pharmacy solution with specific patient access and support services critical to support TARPEYO patients and providers.

PharmacyElite is powered by a dedicated team focused on removing common points of redundancy and improving outcomes throughout the TARPEYO patient journey.

Biologics by McKesson was recently selected  as a specialty pharmacy provider by:

• Takeda Pharmaceuticals as a specialty pharmacy provider for LIVTENCITY^TM(maribavir), indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet.
• PharmaEssentia USA Corporation as a specialty pharmacy provider for BESREMi^®(ropeginterferon alfa-2b-njft) for the treatment of adults with polycythemia vera (PV). BESREMi, previously granted Orphan Drug designation, was approved by the U.S. Food and Drug Administration (FDA) on November 12, 2021. This therapy is an innovative monopegylated long-acting interferon intended for injection once every two weeks or once every 4 weeks during long-term maintenance (after achieving hematological stability for at least one year).

Biologics specialty pharmacy is committed to and recognized for its level of customer service as well as its innovative, high-touch and multidisciplinary patient-centric approach. Each team includes pharmacists with in-depth knowledge of therapies, experienced nurses and financial counselors who are familiar with various financial assistance programs and organizations that help patients.

Takeaway: Biologics by McKesson was one of the main reasons McKesson stock hit a 52-week high in December 2021